MY ACCOUNT | NEWSLETTER |

Returns Between Expectations and Uncertainty


Moving in the markets also means being willing to accept a certain margin of uncertainty: generally, the higher it is, the higher the potential return on your investments. A fundamental variable in the realm of savings and investments is risk (the share of inherent uncertainty intrinsically linked to a specific financial activity).

A specific financial activity is defined as risky when its performance cannot be entirely or at least partially predicted in advance with certainty. Conversely, it is considered low risk and/or risk-free if its performance over time is more easily predictable and/or is capable of guaranteeing a certain cash flow, exposing itself to a lesser extent to the possibility of fluctuations or losses. In simpler terms, an investment is low risk when it ensures at least the preservation of the initial capital for the saver, whereas it is high risk when determining the final extent of the invested capital becomes more challenging (it may even incur significant losses).

Why risk to the point of jeopardizing the invested sum? Is it worthwhile to expose oneself to adverse or difficult-to-tolerate situations? Another fundamental concept in the financial domain comes into play here: return (usually, risk and expected return grow proportionally). Those aiming to increase their initial capital must be willing to take on some additional risk, implementing all strategies useful for containing these risks (e.g., investment diversification), but at the same time being cautious of claims regarding strategies or solutions that promise quick enrichment without any danger.

Savers/investors engaged in financial activities typically do so with the expectation that these activities will yield a positive return (a profit with a plus sign). Setting realistic return goals, risk is the "price" one is willing to pay to preserve (e.g., from inflation erosion) or increase their initial capital. It is, therefore, a difficult-to-quantify entity (unlike returns) and, above all, subjective: risk tolerance (the willingness to bear the non-achievement of set goals or even losses) depends on the financial profile of each saver/investor (taking into account their age, goals, economic and financial availability, etc.).

To evaluate one's risk tolerance, there are no exact formulas, but some common-sense practices can be employed:

  • Taking into account both one's current economic situation and future income prospects in the short and medium term can help quantify the percentage of invested capital one is willing to lose in a certain period (considering one's investment time horizon). This does not mean that the scenario must actually turn out unfavorable; it means defining a "benchmark" in the case of challenging markets.
  • Carefully assessing the risk of the chosen instrument, avoiding hasty or superficial judgments. Personal factors come into play (e.g., past experiences, personal level of financial literacy, one's character, personal capacity to withstand adversities, etc.). Seeking the support of a professional who provides all the necessary information for thoughtful and informed choices and avoids decisions or changes in plans dictated by emotional difficulties in tolerating risks is useful.

Talking about financial risk only in terms of inclination or evaluation is still limited: another fundamental concept is that of risk management (the set of activities that can be implemented to try to control potential uncertainty factors, seeking to limit adverse events and maximize returns). Financial risks should not only be taken into account but can also be professionally managed through adequate planning, which will depend on both assessments and precautions regarding the individual strategy pursued and the decision to rely on multiple activities or instruments that function as a system of checks and balances in the pursuit of the delicate risk-return balance.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Penn Vet Announces Interim Leadership for the Department of Clinical Sciences and Advanced Medicine, and Ryan Hospital

Like0
Dislike0

Parnell Launches nixiFLOR® - First FDA-Approved Generic Florfenicol + Flunixin Combination for BRD

Like0
Dislike0

Comparison of two host cell range variants of feline immunodeficiency virus

Like0
Dislike0

Canine babesiosis: a perspective on clinical complications, biomarkers, and treatment

Like0
Dislike0

The use of growth promoters in swine nutrition: Problems and perspectives concerning public health and swine production

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top